/
ENTX
$1.65+$0.02 (+1.23%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$80.3M
49M shares
52-week range
$0.91 – $3.22
32% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.93%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-4.64
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $500.0K | $236.0K | $365.0K | $571.0K | $134.0K | $0 | $181.0K | $42.0K |
| Cost of revenue | $0 | $448.0K | $300.0K | $373.0K | $165.0K | $56.0K | $172.0K | $42.0K |
| Gross profit | $500.0K | −$212.0K | $65.0K | $198.0K | −$31.0K | −$56.0K | $9.0K | $0 |
| Gross margin | 100.0% | -89.8% | 17.8% | 34.7% | -23.1% | — | 5.0% | 0.0% |
| R&D | $8.5M | $7.0M | $6.4M | $6.8M | $5.8M | $4.5M | $4.5M | $6.0M |
| Operating income | −$10.9M | −$11.5M | −$11.2M | −$12.2M | −$13.1M | −$8.9M | −$9.6M | −$11.5M |
| EBITDA | −$10.8M | −$10.5M | −$11.1M | −$12.2M | −$12.9M | −$8.8M | −$9.5M | −$11.4M |
| Net income | −$10.3M | −$10.8M | −$11.2M | −$12.2M | −$13.1M | −$8.9M | −$9.5M | −$11.4M |
| Net margin | -2060.8% | -4574.2% | -3072.9% | -2134.3% | -9754.5% | — | -5271.3% | -27235.7% |
| EPS (diluted) | -1.29 | -0.90 | -0.54 | -0.47 | -0.45 | -0.31 | -0.25 | -0.25 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $55M | $-0.34 | $-0.34–$-0.34 | 1 |
| 2027 | $5647 | $-0.57 | $-0.57–$-0.57 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.14
Price
$1.65
Implied downside
-92%
Peer comparison
Entera Bio Ltd. Ordinary Shares
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
www.enterabio.com- Employees
- 22
- IPO / List date
- Jun 28, 2018
- HQ
- JERUSALEM
Held by traders on TradeandTell
No one on the platform currently holds ENTX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ENTX as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ENTX yet.
